Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV

Clinical Infectious Diseases

Volumn 56, Issue 7, 2013, Pages 1044-1051

  McMahon, Deborah K ^a   Zheng, Lu ^b   Hitti, Jane ^c   Chan, Ellen S ^b   Halvas, Elias K ^a   Hong, Feiyu ^a   Kabanda, Joseph ^d   Taulo, Frank ^e   Kumarasamy, Nagalingeswaran ^f   Bonhomme, Jerry ^g   Wallis, Carole L ^h   Klingman, Karin L ⁱ   Hughes, Michael D ^b   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e UNIVERSITY OF MALAWI   (Malawi)

^f VHS Medical Centre India   (India)

^g Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

HIV; Mother to child transmission; Nevirapine; Pregnancy; Resistance

Indexed keywords

ALANINE; ANTIRETROVIRUS AGENT; ASPARAGINE; CYSTEINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLYCINE; ISOLEUCINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LYSINE; METHIONINE; NEVIRAPINE; RITONAVIR; TENOFOVIR; TYROSINE; VALINE; ZIDOVUDINE;

ADULT; ALLELE SPECIFIC POLYMERASE CHAIN REACTION; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LABORATORY TEST; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84875025072     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1219     Document Type: Article

References (16)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose NVP compared with zidovudine for prevention of mother- to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET- 012 randomised trial. Lancet 1999; 354: 795-802.
2. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of NVP in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infec Dis 1998; 178: 368-74.
3. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7.
4. Beckerman KP. Long term findings of HIVNET 012: the next steps. Lancet 2003; 362: 842-3.
5. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35: 126-30.
6. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42: 610-3.
7. Kassaye S, Lee E, Kantor R, et al. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV-1: population and clonal sequence analysis. AIDS Res Hum Retroviruses 2007; 23: 1055-61.
8. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child transmission. AIDS 2006; 20: 995-1002.
9. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192: 16-23.
10. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapineresistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103: 7094-9.
11. Lockman S, Hughes M, McIntyre J, et al. The OCTANE 5208 Study Team. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363: 1499-509.
12. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach - 2010 version. Geneva, Switzerland: World Health Organization, 2010.
13. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6:e1000172.
14. Palmer S, Boltz V, Chow J, et al. Short-course combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antiviral Therapy 2012; 17: 327-336.
15. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 2011; 108: 9202-7.
16. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIVinfected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis 2012; 54: 285-93.